Focal Segmental Glomerulosclerosis clinical trials
22 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
- A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
- AMPK-activation by Metformin in FSGS: AMP-FSGS
- Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
- An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
- Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- taVNS for FRNS in Children
- A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
- Atacicept in Multiple Glomerular Diseases
- Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
- Study of WAL0921 in Patients With Glomerular Kidney Diseases
- PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
- Proteinuria in Pre and Post Transplant
- Nephrotic Syndrome Study Network
- Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
- NEPTUNE Match Study
- SLIT ABS: Study on Patients With Autoimmune Podocytopathy
- Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Focal Segmental Glomerulosclerosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.